*FDA-approved in 1985, the first GnRHa for the treatment of advanced prostate cancer.2
Lucas, age 64
Semi-retired financial analyst, passionate cook,
husband and father
Not an actual patient.
LUPRON DEPOT, an androgen deprivation therapy (ADT), has been a pioneer in the treatment of advanced prostate cancer.2
A Wealth of Experience
Our commitment to your patients will be as strong tomorrow as it is today.
#1 Prescribed
America’s most-prescribed
GnRHa3†‡
35+ Years
The most clinical experience of
any GnRHa on the market2§
Millions of injections
administered4||



A Number of Firsts
From day 1, LUPRON DEPOT has been committed to the treatment of advanced prostate cancer.
Coverage and Affordability
We are committed to making LUPRON DEPOT accessible and affordable for patients.
>99%
of patients
LUPRON DEPOT is covered* for >99% of patients with commercial insurance, Medicaid, and Medicare Part B combined5
100%
covered
LUPRON DEPOT is covered* by 100% of Medicare Part B plans5†
Overview of Medicare Part B and D
Medicare
Part B
Most LUPRON DEPOT patients are covered* through Medicare Part B.
Part B is a medical benefit that covers services such as in-office administration for medications like LUPRON DEPOT
Part B may offer lower out-of-pocket costs for patients compared with Part D or commercial pharmacy benefits
Medicare
Part D
Part D is a prescription drug benefit that covers medications dispensed through a pharmacy
Part D may have higher out-of-pocket costs than Part B
* | Covered means the product is not NDC (National Drug Code) blocked as of 2020. Restrictions may apply. Percentage covered reflects known status for medical insurance coverage only. |
† | For those Commercial and Medicare plans that report coverage data; excludes plans and payors with unknown coverage. |
Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
"...decades of experience in using LUPRON DEPOT in my practice continues to reinforce my confidence in prescribing it as my first choice for patients with advanced prostate cancer"